On October 15, 2020 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, reported that biomarkers associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac combination therapy will be presented at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting (Press release, IMV, OCT 15, 2020, View Source [SID1234568520]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Title:
Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
Poster Presentation Details:
Presenter: Neil Berinstein, MD, FRCPC, ABIM
Hematologist at the Sunnybrook Health Science Centre, Toronto.
Abstract Number: 356
Important dates:
November 9 – 8.00am EST: Full abstract will be released on the SITC (Free SITC Whitepaper) meeting platform,
November 11 – 9.00am EST: Poster will be posted on Company’s website and poster presentation will be available on the SITC (Free SITC Whitepaper) conference platform,
November 12 – 8.00am EST: Company will discuss data during a live webcast,
November 12 from 4.50-5.20pm EST and November 14 from 1.00-1.30pm EST, a Q&A session will be held on the SITC (Free SITC Whitepaper) meeting platform.
The final poster presentation will include additional data collected between the abstract submission on April 1, 2020 and the presentation itself. The poster will be available under the Scientific Publications & Posters section on IMV’s website on the day of presentation.
Webcast registration will be available under "Events, Webcasts and Presentations" in the Investors section of IMV’s website. The video recording will be available for replay shortly thereafter.
About DPX-Survivac
DPX-Survivac is the lead candidate in IMV’s new class of immunotherapies that generates targeted and sustained immune response in vivo. Treatments with DPX-Survivac have demonstrated the potential for sustained and targeted cancer cell killing capabilities with limited adverse events.
DPX-Survivac consists of survivin-based peptides formulated in IMV’s proprietary DPX drug delivery platform. DPX-Survivac is designed to work by eliciting a cytotoxic T cell immune response against cancer cells presenting survivin peptides on their surface.
Survivin, recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen, is broadly over-expressed in most cancer types, and plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to chemotherapies. IMV has identified over 20 cancer indications in which survivin can be targeted by DPX-Survivac.
DPX-Survivac has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as maintenance therapy in advanced ovarian cancer, as well as orphan drug designation status from the U.S. FDA and the European Medicines Agency (EMA) in the ovarian cancer indication.
DPX-Survivac is currently being evaluated in three Phase 2 studies: advanced ovarian cancer, relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and a basket trial of five solid tumors. All of which are expected to report topline results in 2020.
About the SPiReL Study
"SPiReL" is a Phase 2 non-randomized, open label, efficacy and safety study of a novel immunotherapy combination with DPX-Survivac and pembrolizumab. Intermittent low dose cyclophosphamide is given as an immune-modulator. Subjects with r/r incurable DLBCL and survivin expression are eligible for participation. The primary outcome is to document the objective response rate using modified Cheson criteria to the combination treatment. Secondary outcomes include the documentation of: changes in tumor volume, toxicity profile, duration of response (Cheson criteria).